Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Actually holding up fairly well with paltry volume and no fresh news. No real interest to buy or sell. Waiting on next 8-K or a PR. 3rd quarter 10-Q due 11/14 so maybe something in that. Drips slowly down recently but good news will turn it around quickly.
Many Bio's have no drug on the market but have market cap in hundreds of million dollars. It's all about progress and anticipation. Colin knows all about the system and how to get NDA (new drug applications). Study his bio. He's in control and will be moving one of the INSPYR drug platforms along shortly. That's what he does and is good at!
No brainer!! News WILL come and this WILL rocket!!
Don't let your thoughts waiver from the fact that in march this ticker went from .004 to .0378 in 4 days and again in october it went from .003 to .0718 in 3 days. It may fluctuate down with no news and little volume but HISLOP didn't take control to let things stagnate like it did under Lowe/Cain lack of management!
We finally can agree on something: Craziest CEO hire in corporate history. Obviously he was put in that position by someone but who. I believe it was Silvestre (attorney) but after a year and a half I hope he got paid something for rubber stamping all those papers!
On July 26, 2019, the Company appointed Michael Cain to serve as the interim chief executive officer, chief financial officer, president, and as a member of the Board. Mr. Cain will serve on an interim basis as principal executive and financial officer on an at-will basis. The Company is not a party to any employment agreement or contract related to Mr. Cain’s employment and he will not receive any compensation at this time.
Newbie making some grand prediction's...I Like it.. way to go!!! Always good to get additional opinions no matter which way they are leaning!
Typical with nspx..low volume slide until it runs to .04+ like it did in March or .07 like it did in Oct.. the next time the run may be .10+.. be there or be square.
After a long wait navigating the bureaucracy (Applied 2016) of the USPTO the patent for commercial production of thapsigargin was issued to Phyton today. Now Phyton holds patents for commercial production of thapsigargin in both Europe and United States
PR from 2015:
GenSpera, Inc. (now Inspyr) announced a strategic partnership with Phyton Biotech for the manufacture of thapsigargin, which is derived from the thapsia plant and is the key ingredient in the company's investigational agent mipsagargin.
Ridgeway officially took control of NSPX with the 8-K of 10/8 (less than one month ago). Since then there has been filings indicating Ridgeway is cleaning up loose ends and getting financially sound! These actions may have a short term negative on PPS but now that Ridgeway/Inspyr is set up expect news of the drug platforms. This entire exercise that has developed is certainly NOT for Ridgeway/Inspyr to sit on their hands (they have 500K cash and 1 Billion shares to sell to investors if they need cash)
No biggie.. all know about the raise in AS! Spooked some weak hands nothing has changed ..waiting for a meaty 8-K!!!
In the revised prer 14c posted today it was reported that there were $2,096,488 outstanding convertible debenture debt..but in the 8-K dated 10/29 in explaining the new $600,000 debenture it stated that ii $100,000 was for cancellation of outstanding indebtedness to existing investors. If that's the case WOW what a deal. Get rid of 2m debt for 100K!
Agreed.. nothing toxic about that financing. A new beginning. All old debt gone for 100K.. no interest loan of 600K for 1 yr.. reasonable convertible pricing for Sabby..fair on both sides. Sabby made $$$ on last two spikes and know it will make more as this tickers pps runs up!
Tuesday may be a significant milestone in the potential development of MIPSAGARGIN. The strategic partnership that was formed between Genspera (now Inspyr) and Phyton Biotech in 2015 for the production of thapsigargin (main ingredient in Mipsagargin) finally after years will finally have some viability. Phyton will officially be issued the patent for the PCF (plant cell fermentation) production of thapsigargin on 11/03/2020. USPTO # 10822628.
This may alleviate one of risk factor noted in recent 10-K
Our therapeutic compounds may not be able to be manufactured profitably on a large enough scale to support commercialization.
To date, prior to our curtailment of operations, our therapeutic compounds have only been manufactured at a scale which is adequate to supply our research activities and early-stage clinical trials. There can be no assurance that the procedures currently used to manufacture our therapeutic compounds will work at a scale which is adequate for commercial needs. In the event our therapeutic compounds cannot be manufactured in sufficient quantities for commercialization, our future prospects could be significantly impacted and our financial prospects would be materially harmed.
nice for sabby.. convert 600k @.02 (30mil) sell @.06..nice work if you can find it! Expect a meaty 8-K on the horizon.
Two success stories for COLIN HISLOP:
While at Peninsula he developed Doripenem for systemic infections. Peninsula was bought by J&J and Doripenem has world wide sales in 100 millions.
While at CV Therapeutics developed Ranexa for angina. CV was bought by Gilead and Ranex had yearly sales of 748 million (2016)
Now this heavy hitter is in control of Inspyr.
The novel oncology delivery technology RT-AR001 (Ridgeway Therapeutics - Adenosine Receptor 001) enables the patients own immune system suppress tumor growth. With the current developments (raising AS and debt financing of 500K) look for NSPX to soon move this technology forward and possibly a NDA (new drug application) will surface soon. In a short month Colin Hislop has set the stage for developments in NSPX which just a short time ago were deemed not possible.
Sabby first came on the scene in July 2015 and has been the major benefactor keeping Genspera then Inspyr alive. In total they have invested millions and in return make additional profit on converting low and selling higher.. I doubt that will change..75K is a nice return but there are larger $$$ to be had!
Ridgeway plan is taking shape..
Step 1. 8-K 10/8... take control of Inspy
Step 2. pre 14-c 10/16.. make sure there are sufficient shares to progress their drug platforms.
Step 3. 8-K 10/29.. a new beginning.. get rid of old debt.. get some working capital ($500,000) extend new debt until 10/21.
Step 4. ??? advancement on drug platforms, partners, license, new studies and/or NDA (new drug applications) coming soon.
Colin knows how all this works he won't get ahead of himself! One step at a time.
So correct! Sabby is not interested in owning shares they are interested in making $$$. They will convert @.02 when they can immediately sell much higher.
Changes start to roll out after 8-K of 10/8..Colin now has 500k to start his work as main man at NSPX. Good to see 8-Ks after nspx has been silent for so long. They will come regularly now a real bio man is in control. Lots of good coming to this ticker.
not a bad deal.. nspx gets current debt due 12/31 canceled $500,000 cash to start work on drug related issues. New debt due 10/23/21 Sabby gets to convert into new shares @.02 or lower. Got to start this new Ridgeway/Inspyr deal some where and I guess this is where it starts. Looks like Sabby is looking for another spike in price to make some serious cash!
Even if I would contact him (don't need to) I wouldn't know what to say to him that wouldn't display my ignorance in matters way above my pay grade. Plus I wouldn't expect any answer that has the hint of insider information from such a seasoned veteran of the biotech industry. Like calling him and he is going to talk extensively to a stranger and pinkie trader concerning the details of the goings on with Ridgeway/Inspyr. LOL
Know what you own...
Colin also has control of all the drug platforms that Inspyr acquired from the merger with L&C! Multiple Myeloma extremely nasty .. a good friend died of that monster!
A2A/A2B antagonists for a range of tumors, as a mono- or combination therapy, including:
Solid tumors, e.g., breast, colorectal, melanoma, lung, prostate, bladder
Hematological malignancies, e.g., multiple myelomas, acute lymphocyte leukemia
An A2A agonist patch or cream/gel for auto-inflammatory/autoimmune diseases, such as:
Rheumatoid Arthritis/psoriasis
Crohn’s Disease/ulcerative colitis
Diabetic nephropathy
Sickle-Cell Disease
Immune system disorders, e.g., Graft-vs.-Host-Disease
Diabetic foot ulcers/hard-to-heal wounds
Bacterial infections, e.g., Clostridium Difficile, Sepsis
Oral A2B antagonists, with the potential to address:
Asthma
Type 2 diabetes
Atherosclerosis
And unique A2A agonists for specialty indications:
Stress imaging – a highly selective compound with the potential to significantly reduce side effects versus currently marketed products
Glaucoma –a highly potent, hydrophobic compound as ophthalmic drops
Local pain –a compound with very good skin penetration for a lower back pain patch, and a cream/gel for hand, elbow and knee arthritis pain and inflammation
Know what you own..
The plant thapsia garganica (natural thapsigargin) got the moniker the (DEADLY CARROT) because camels on trade routes in northern africa were attracted to it'd bright orange flowers ate the plant and soon died. Thapsigargin is a natural born killer. Scientists at John Hopkins harness this toxic killer into a safe tumor killing prodrug mipsagargin. Mipsagargin is a designated orphan drug secured by patent until 2034. Inspyr holds the patent for the production of mipsagargin. Until now thapsigargin (mipsagargin active ingredient) was difficult and expensive to produce (a 45 step process from plant). That has changed by PHYTON BIO receiving a patent for PCF (plant cell fermentation) production of thapsigargin.
With the changes in control of Inspyr, it's not out of realm of possibility that a renewal of interest in Mipsagargin surfaces.
Right on.. prior to Colin taking control the ticker had no one who could make any scientific decisions and a fire sale of patents and IP was where the ticker was going! That has all changed! With Colin on board and in control look for a possible ph III mipsagargin trial and NDA (new drug application) for various adenosine based drugs!
Before you make a mistake..
Read all you can concerning mipsagargin the "CANCER GRENADE" and it's active ingredient thapsigargin the "DEADLY CARROT" that is known to be 10 to 100 times more potent than standard chemo-therapy. And don't forget that PHYTON BIOTECH will get the patent to produce thapsigargin in commercially attractive quantities and prices on 11/03/2020. PHYTON is the same biotech that is the world largest producer of TAXOL for various cancers. Taxol is also a plant based drug. NSPX holds various patents for mipsagargin that are now in control of COLIN HISLOP et al to develop, sell, or partner!! NSPX didn't spend 60 million developing the platform to trash it.
Read all you can concerning what NSPX received from L&C. Adenosine super antagonist that gets to the heart of why cancer develops and how the L&C drug platform supercharges the immune system in fighting off cancer development in solid tumors. Adenosine is also in cutting edge development for a host of other diseases from asthma (lung disorders) solid tumors, bacterial infections and many more.
Now a seasoned Bio scientist (COLIN HISLOP)(read his bio) is in control of this varied stash of ammo to develop some potent drugs that will help all in disease therapy.
Don't let a low volume slide take you out of this ticker..it has happened before only to leave some behind when it shoots up in a hurry. Ridgeway didn't make the move to control the stock to leave if gathering cobwebs in some laboratory. Move will come fast so be alert. History will repeat! .003 to .07+ WOW!!!
Yes a name change would be a great thing. Inspyr was supposed to be a move forward event when the name got changed from Genspera in 2016. What it turned into was a complete miss management of the drug platforms and financing by totally clueless so called experts (your ears ringing chris lowe). At this point after 3 RS and total silence for years Inspyr reeks of bad faith, shareholder abuses and talk of corporate scams. Someone taking over control of this ticker was the best and inevitable event that was going to save NSPX. Ridgeway is in control now ..let's give them best of luck and see what happens.
In the 8-K dated 10/8.."Accordingly, the board of directors of the Company has determined that a change in control of the registrant has occurred".
Inspyr is now just a bystander as Ridgeway has taken full control of NSPX. Michael Cain will probably remain as CEO and figurehead/rubber stamper of any and all that Hislop requires of him to execute. The long unabated silence and miss-management of NSPX by the totally inept may be over.
It certainly appears that Ridgeway worked on the adenosine antagonist therapy they received from Inspyr in 2018 and enhanced the drug into the novel immuno-oncology delivery technology RT-AR001. The original agreement called for 12mil in success based payments plus royalties. It is very possible the COLIN HISLOP has determined the projected value of RT-AR001 is substantially higher and wants Inspyr to a) own the drug.. b) Ridgeway own 65 mil shares and c) control of Inspyr along with 1 Billion of AS to develop all the IP of Inspyr. The whole purpose is for Ridgeway (COLIN HISLOP and his backers)to completely take over Inspyr.
And make Ridgeway 65 mil shares worthless..right! Anyway notes aren’t due until end of year.. anything can happen by then!
As the ticker moves higher the weak bag holders from 2.5-4 from last spike may bail and keep a lid on the up trend and could even cause another pps retreat but eventually they will get washed out. With additional news (it's coming) from COLIN this ticker may move substantially higher.
The 8-K from 10/8 is NOT old news and will have a lasting effect on this ticker. Just getting started. Traders will jump in as they did friday to drive this higher. Obviously there will be pull backs as traders take profits and momentum ebbs and flows (the nature of pinkies). It moves fast in either direction so be alert.
Not a lot of patience going around. like today a good run up to high 2's until those holding 2-2.5 from last run bailed with some pennies and those who have been long in the 1's from early in the week also bailed with more pennies. Long stair step up moves are not common in a traders market.
Once again ran up on just a whiff of news on twitter! When real news come out (and it will) it will be like chasing Usain Bolt.. you won't catch it! LOL
In all the daily noise lets not forget:
1. Phyton Biotech will be issued the patent to commercially produce thapsigargin (active ingredient in Mipsagargin) on 11/3/20. This opens up a viable supply chain for the quantity need for further clinical trials of mipsagargin. USPTO patent #10822628
2. Medicinova is in the process of starting investigative studies of their drug MN-166 (ibudilast) in combination with other drugs including MIPSAGARGIN! for the treatment of Glioblastoma (brain cancer)
3. The newly obtained immuno-oncology delivery technology that is adenosine based and enhanced by Ridgeway has many possibilities in cancer and other therapies.
Any news on any of these fronts or other developments will have a positive effect on NSPX going forward. Colin has his thumb on exactly what will move NSPX along and it may be exciting.
Load up before the boat leaves the dock.. this ticker runs up fast on any whiff of positive news .. and you know with resent developments it's only time before that news hits. Don't be left behind. Colin and Ridgeway didn't come on board to stay idle for long. Don't worry about the pennies there are dollars to be had!!
Michael Cain is ceo to rubber stamp documents and provide a figure head for NSPX. He is not capable of progressing the drug platforms. At least with Colin in the mix there is a seasoned biotech professional associated with the ticker. No matter what is in the future you can be assured Colin is not going to be part of some penny stock scam to fleece investors.
That's a plan that worked after last two RS. The slow erode into sub pennies gave opportunity to load up cheap knowing that this ticker runs fast when it takes off. Will have to see what happens this time! The Ridgeway deal may change things.
The wash out from that super move up continues. It is the second or third time a run up has followed with a low volume rinse and left many questions. Its also has left for some reason (manly losses)some disgruntled investors who continue to warn naive traders of the perils of investing in NSPX. Like it needs to be told!